Global Pezolerocept Market Strategic Research Report

Scope of the Report

The global Pezolerocept market size is predicted to grow from US$ 83.15 million in 2025 to US$ 445 million in 2032; it is expected to grow at a CAGR of 12.9% from 2026 to 2032.

Spesolimab is a humanized monoclonal antibody targeting the interleukin-36 receptor (IL-36R), a targeted immunological biologic agent. It specifically binds to and blocks the IL-36 receptor signaling pathway to suppress excessive inflammatory responses in the skin and related tissues. Primarily indicated for the treatment of autoinflammatory skin diseases such as generalized pustular psoriasis, it represents a precision-targeted therapy against the pathogenesis of pustular psoriasis, characterized by rapid onset and high specificity in clinical practice.In 2025, global Spesolimab production reached approximately 18,000–22,000 vials

Spesolimab, the world’s first IL-36 receptor-targeted biologic exclusively developed for generalized pustular psoriasis (GPP), holds a first-in-class monopoly in the global rare dermatology market by addressing a long-standing unmet medical need with its precise mechanism that blocks the core inflammatory pathway and rapidly controls life-threatening symptoms. Approved in over 40 countries and regions worldwide, its global commercialization has been fully transferred to LEO Pharma, which leverages its specialized dermatology platform and global network to enhance disease awareness and treatment access. Positioned as a high-value orphan drug, it adopts a premium pricing strategy supported by strong clinical evidence; despite a limited patient population, it benefits from a clear competitive landscape with no direct same-target competitors, and its long-term growth hinges on indication expansion, approval of subcutaneous maintenance therapy, and broader insurance coverage. Characterized by a niche but essential market, specialty-driven promotion, global footprint, and indication-led expansion, spesolimab is poised to unlock broader potential in IL-36-mediated autoinflammatory skin disorders as research and clinical adoption advance.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Pezolerocept market?

What factors are driving Pezolerocept market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Pezolerocept market opportunities vary by end market size?

How does Pezolerocept break out by Type, by Application?

This report presents a comprehensive overview of the global Pezolerocept market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 450 mg/7.5 mL
• 150 mg/mL

Segment by Route of Administration

• Intravenous Infusion
• Subcutaneous Injection

Segment by Combination Therapy

• Combined With Conventional Immunosuppressive Agents
• Combined With Topical Glucocorticoids

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Application

• Treatment Of Generalized Pustular Psoriasis
• Treatment Of Palmoplantar Pustulosis
• Treatment Of IL-36 Mediated Autoinflammatory Skin Diseases
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pezolerocept market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Treatment Of Generalized Pustular Psoriasis, Treatment Of Palmoplantar Pustulosis, Treatment Of IL-36 Mediated Autoinflammatory Skin Diseases evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact